(RTTNews) - Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status. The findings were demonstrated in an expanded MRD analysis of the Phase 3 CEPHEUS study and a post hoc analysis of clinically relevant subgroups in the Phase 3 AURIGA study.
The New analysis from Phase 3 CEPHEUS study demonstrated 85 percent of patients who achieved MRD negativity with DARZALEX FASPRO were progression free at 4.5 years. The Subgroup analysis from Phase 3 AURIGA study showed higher rates of MRD-negative conversion in patient populations disproportionately impacted by multiple myeloma.
According to the company, data from the expanded MRD analysis of the Phase 3 CEPHEUS study showed the addition of DARZALEX FASPRO to bortezomib, lenalidomide and dexamethasone (D-VRd) leads to improved and deepened rates of overall and sustained MRD negativity versus VRd alone, and shows significantly improved progression-free survival. CEPHEUS is the fifth Phase 3 study showing the addition of DARZALEX improves depth and duration of response, leading to improved progression-free survival.
In a post hoc analysis of the Phase 3 AURIGA study, an investigational maintenance regimen of DARZALEX FASPRO combined with lenalidomide resulted in consistently improved MRD-negative conversion rates after 12 months. These results were consistent across anti-CD38 naïve patient subgroups who were MRD-positive post-autologous stem cell transplant (ASCT). In patients older than 65 years, MRD-negative rates were higher when treated with D-R maintenance therapy compared to R alone. Maintenance therapy with D-R showed a consistently higher conversion to MRD negativity in Black patients compared to R alone and white patients.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
